高级检索
当前位置: 首页 > 详情页

miR-17 inhibits ovarian cancer cell peritoneal metastasis by targeting ITGA5 and ITGB1

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obster & Gynecol, Wuhan 430010, Hubei, Peoples R China [2]Hubei Univ Chinese Med, Sch Pharm, Dept Med Chem, Wuhan 430065, Hubei, Peoples R China [3]Hubei Univ Arts & Sci, XiangYang Cent Hosp, Dept Oncol, Xiangyang 441021, Hubei, Peoples R China
出处:
ISSN:

关键词: miR-17 integrin alpha 5 beta 1 adhesion peritoneal metastasis ovarian cancer

摘要:
An essential step in the peritoneal spread of ovarian cancer is the adhesion and implantation of tumor cells to the mesothelium layer. Integrin alpha 5 and beta 1 have been reported to mediate the initial adhesion process and to correlate with disease survival in ovarian cancer. However, the molecular mechanism of integrin alpha 5 beta 1 dysregulation in tumorigenesis and metastasis remained enigmatic. In the present study, using the US NCI60 database, we identified miR-17 as a candidate regulator targeting both integrin alpha 5 and beta 1. The level of miR-17 was evidently inversely correlated with that of alpha 5 and beta 1 in ovarian cancer cell lines. Specifically, miR-17 bound directly to the 3' untranslated region (3'UTR) of alpha 5 and beta 1 and suppressed their expression. Forced expression of miR-17 led to markedly diminished adhesion and invasion of ovarian cancer cells in vitro, and notably reduced metastatic nodules inside the peritoneal cavity in in vivo SKOV3 xenografts model. Moreover, ectopic expression of miR-17 in ovarian cancer cells resulted in repressed ILK phosphorylation as well as decreased production of active matrix metalloproteinase-2 (MMP-2). Our results indicated that miR-17 hampered ovarian cancer peritoneal propagation by targeting integrin alpha 5 and beta 1. These findings supported the utility of miR-17/alpha 5 beta 1 to be considered as valuable marker for metastatic potential of ovarian cancer cells, or a therapeutic target in ovarian cancer treatment.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2014]版:
Q3 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obster & Gynecol, Wuhan 430010, Hubei, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obster & Gynecol, Wuhan 430010, Hubei, Peoples R China [2]Hubei Univ Chinese Med, Sch Pharm, Dept Med Chem, Wuhan 430065, Hubei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:0 总访问量:408 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)